SIETES :: 92793 citas

Resultados de la búsqueda por DEPENDENCIAS REFINAR BÚSQUEDA

1.

Sànchez G. Catalunya se erige en huerta europea del gran negocio de la marihuana. El Periódico 2019:3 de junio. [Ref.ID 103128]

2.

Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]

3.

Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]

4.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ 2019;365:4 de abril. [Ref.ID 103086]

5.

Torjesen I. Pregabalin and gabapentin: what impact will reclassification have on doctors and patients?. BMJ 2019;364:11 de marzo. [Ref.ID 103081]

6.

Sánchez Caballero D. La ONU mantiene el estatus del cannabis, que sigue al mismo nivel de control que la heroína pese a la recomendación de la OMS. eldiario.es 2019:16 de abril. [Ref.ID 103078]

7.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

8.

Walters J. Más de 500 ciudades y tribus nativas de EEUU demandan a una sola familia por provocar "la peor crisis de la droga de la historia" . eldiario.es 2019:24 de marzo. [Ref.ID 103063]

9.

Hurley R. Medical cannabis: no NHS patients have benefited from law change, say campaigners. BMJ 2019;364:15 de febrero. [Ref.ID 103033]

10.

Gobbi G, Atkin T, Zytnski T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N, Mayo N. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. A systematic review and meta-analysis. JAMA Psychiatry 2019;76:13 de febrero. [Ref.ID 103030]

11.

Hajek P, Phillips-Waller A, Przulj D, Pesola F, Smith KM, Bisal N, Li J, Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med 2019;380:14 de febrero. [Ref.ID 103022]

12.

Thielking M. Federal trial over fentanyl bribes gets underway. STAT Morning Rounds 2019:2. [Ref.ID 103007]

13.

Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA 2018;320:27 de noviembre. [Ref.ID 102915]

14.

Thielking M. FDA panel says overdose antidote should be prescribed with opioids. STAT Morning Rounds 2018:3. [Ref.ID 102906]

15.

Mayor S. Pregabalin and gabapentin become controlled drugs to cut deaths from misuse. BMJ 2018;363:16 de octubre. [Ref.ID 102878]

16.

Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. National Vital Statistics Reports 2018;67:12 de diciembre. [Ref.ID 102871]

17.

Strang L, Taylor J. Heroin-assisted treatment and supervised drug consumption sites: experience from four countries. Rand Corporation, Santa Monica, California 2018:5 de diciembre. [Ref.ID 102861]

18.

Schroeder AR, Dehghan M, Newman TB, Bentley JP, Park KT. Association of opioid prescriptions from dental clinicians for US adolescents and young adults with subsequent opioid use and abuse. JAMA Intern Med 2018:3 de diciembre. [Ref.ID 102858]

19.

Thielking M. Life expectancy down as suicides, overdoses rise. STAT Morning Rounds 2018:2. [Ref.ID 102856]

20.

Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102851]